Form 4: Kyverna Therapeutics Director Acquires Stock Options
SEC Form 4 Filing
Christi Shaw, a director at Kyverna Therapeutics, acquired stock options for 38,679 shares of common stock on February 14, 2025.
Summary
- On February 14, 2025, Christi Shaw, a director of Kyverna Therapeutics, acquired stock options to purchase 38,679 shares of the company's common stock.
- The exercise price of these options is $3.03 per share.
- The options vest fully on October 30, 2025, contingent upon Ms. Shaw's continuous service as an advisor to the company.
- The options expire on February 14, 2035.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing regarding stock option grants, which is neither particularly positive nor negative.
Industry Context
This is a standard Form 4 filing, reflecting a director's acquisition of stock options, a common form of executive compensation in publicly traded companies.
Stakeholder Impact
- The acquisition of stock options by a director can be seen as a positive sign, aligning the director's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 02/14/2025 | Date of the stock option transaction. |
| 10/30/2025 | Vesting date for the stock options. |
| 02/14/2035 | Expiration date for the stock options. |
| 02/19/2025 | Date of the Form 4 filing. |
Keywords
stock options, Kyverna Therapeutics, director, Christi Shaw, Form 4, beneficial ownership, equity securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.